Abolish the Last Great Plantation in America Resolution

Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act

Client expense: $3,550,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act H.R. 6703 Lower Health Care Premiums for All Americans Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act

Client expense: $3,550,000 · Firm income: Not reported

Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act

Client expense: $2,580,000 · Firm income: Not reported

Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)

Client expense: $2,580,000 · Firm income: Not reported

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act

Client expense: $3,550,000 · Firm income: Not reported

Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025

Client expense: $3,550,000 · Firm income: Not reported

Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act

Client expense: $2,580,000 · Firm income: Not reported

Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)

Client expense: $2,580,000 · Firm income: Not reported

American Innovation and R&D Competitiveness Act of2025 (H.R.1990) (S.1639), make the immediate R&D expensing retroactive to 2022 and permanent. American Innovation and Jobs Act (No bill number) make the immediate R&D expensing retroactive to 2022 and permanent. American Investment in Manufacturing and Main St Act (H.R.1347) (S.559), support reinstatement of the Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) measure. Accelerate Long-term Investment Growth Now (ALIGN) Act (H.R.574) (S.187), support making expensing for American investments in machinery and equipment permanent. The Tax Cuts and Jobs Act (TCJA) implementation, general business tax issues (P.L.117-169). Global tax activities and discussions on Pillar One and Pillar Two at OECD (No bill number). Budget Reconciliation process (H. Con Res 14). Inflation Reduction Act of 2022, implementation of business tax provisions (P.L. 117-169). Big Beautiful Bill, TCJA business provisions, IRA energy provisions. (P.L. 119-21).

Client expense: $770,000 · Firm income: Not reported

Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE) Issues related to direct-to-consumer advertising Issues related to obesity disease awareness and treatment Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Insuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

Client expense: $3,610,000 · Firm income: Not reported

Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to obesity disease awareness and treatment Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Insuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

Client expense: $3,610,000 · Firm income: Not reported

American Innovation and R&D Competitiveness Act of 2023 (H.R.1990) make the immediate R&D expensing retroactive to 2022 and permanent. American Innovation and Jobs Act (No bill number) make the immediate R&D expensing retroactive to 2022 and permanent. American Investment in Manufacturing Act (No bill number) support reinstatement of the Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) measure. Accelerate Long-term Investment Growth Now (ALIGN) Act (H.R.574) (S.187), support making expensing for American investments in machinery and equipment permanent. The Tax Cuts and Jobs Act (TCJA) implementation, general business tax issues (P.L.117-169). Global tax activities and discussions on Pillar One and Pillar Two at OECD (No bill number). Budget Reconciliation process (H. Con Res 14). Inflation Reduction Act of 2022, implementation of business tax provisions (P.L. 117-169).

Client expense: $1,460,000 · Firm income: Not reported

Issues related to health care workforce shortages Issues related to funding for the Early Hearing Detection and Intervention Act (Public Law 117-241) and screening for Cytomegalovirus Various issues related to implementation of the ACA, including Essential Health Benefits and marketplace plans Various issues related to non-discrimination legislation and regulation Issues related to coverage of gender-affirming care/gender-affirming voice therapy Issues related to health information technology, including interoperability Issues related to funding in Fiscal Year 2025 for programs administered by the Department of Health and Human Services and National Institutes of Health H.R. 2332/S. 1101, States Handling Access to Reciprocity for Employment Act Issues related to coverage of and support for individuals who stutter through federal health programs Issues related to consolidation in the health care industry. H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 Senate amendment to H. Con. Res. 14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.

Client expense: $450,000 · Firm income: Not reported

House Bills H.R. 603, the Raise the Wage Act of 2021 - oppose. H.R. 842, the Protecting the Right to Organize (PRO) Act of 2021 - oppose. H.R. 1319, the American Rescue Plan Act of 2021 - oppose. H.R. 7, the Paycheck Fairness Act - oppose. H.R. 1712, the Death Tax Repeal Act - support. H.R. 1799, PPP Extension Act of 2021 - support. H.R. 1381, the Main Street Tax Certainty Act - support. Amendment #184 to H.R. 3684, the INVEST in America Act - support. H.R. 3104, the Get Americans Back to Work Act - support. H.R. 3185, the Save Local Business Act - support. H.J.Res. 22, use the CRA to disapprove the Update of Commissions Conciliation Procedures finalized by the EEOC - oppose. H.R. 2583, the PPP Equity Act of 2021 - support. Herrera Beutler Amendment to H.R. 3110, PUMP Act - support. H.Con.Res. 14, Fiscal Year 2022 Budget Resolution - oppose. Sec. 804 of H.R. 4350, the National Defense Authorization Act for Fiscal Year 2022, Minimum Wage for Employees of Department of Defense Contractors - oppose. Amendment in the Nature of a Substitute (AINS), to comply with S. Con. Res. 14, the Fiscal Year 2022 Budget Resolution - oppose. H.R. 3725, the Relief and Equity for Small Businesses through Tax (REST) Act - support. Tax Fairness for the Self-Employed Act - support. H.R. 5318, Commonsense Reporting Act - support Senate Bills Amendments 767 and 301 to S.Con.Res. 5 - support. Amendment 69 to S.Con.Res. 5 - support. Portman amendment to H.R. 1319, the American Rescue Plan Act of 2021 - support. Sanders amendment to H.R. 1319, the American Rescue Plan Act of 2021 - oppose. S. 53, the Raise the Wage Act of 2021 - oppose. S. 617, the Death Tax Repeal Act of 2021 - support. S. 403, the Fair and Open Competition Act - support. H.R. 1799, PPP Extension Act of 2021 - support. S. 480, the Main Street Tax Certainty Act - support. S. 420, the Protecting the Right to Organize (PRO) Act of 2021 - oppose. S. 1555, the Get Americans Back to Work Act - support. S. 1636, the Save Local Business Act - support. S.J.Res.13, use the CRA to disapprove the Update of Commissions Conciliation Procedures finalized by the EEOC - oppose. S. 2239, the Unnecessary Agency Regulations Reduction Act of 2021 - support. Amendment 3292 to S.Con.Res. 14 - support. Amendment 3106 to S.Con.Res. 14 - support. Statement for the Record/Testimony Statement for the record for the hearing entitled, The Right to Organize: Empowering American Workers in a 21st Century Economy, before the Senate Committee on Health, Education, Labor, and Pensions. The implicit focus of this hearing is S. 420, the Protecting the Right to Organize (PRO) Act of 2021. NFIB opposes S. 420, the PRO Act of 2021. (July 22, 2021) NFIB members Jan Haviland, Mark Lunde, Greg Owens testified before Congress on National Small Business Week: Celebrating our Main Street Champions. (September 14, 2021) Other Issues Stepped-up basis - support Build Back Better Act - oppose Transparency in operations of Pharmacy Benefit Managers (PBMs) - support Revision of the Navigable Waters Protection Rule (NWPR) - oppose Comments Environmental Protection Agency and Department of the Army Notice Titled Notice of Public Meetings Regarding Waters of the United States; Establishment of a Public Docket; Request for Recommendations, 86 Fed. Reg. 41911 (August 4, 2021).